InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by JEAN LOUIS MENARD, Director. Insider active across 1 companies, notably GENOWAY. In total, 1 filings have been recorded. Total volume traded: €90k. The latest transaction was disclosed on 17 December 2025 — Acquisition. Regulator: AMF. All data is accessible without signup.
Declarations1 total
€90,47538,500 shares@ €2.350.26% mcap100.0% of flow
ActionEuronext Paris
2025DD1086013·
Ideal exit: 13 Sept 2026 (T+270)
1 of 1 declaration
About JEAN LOUIS MENARD
Jean-Louis Ménard is an experienced healthcare and life sciences executive and currently serves as a director of genOway. Trained as a physician and holding a Master’s degree in Law from the University of Lyon 3, he built a career at the intersection of biomedical innovation, industrial development, and corporate strategy. He began in the mergers and acquisitions department of Banque de l’Union Européenne before joining Sanofi in 1994. At Sanofi, he held a series of senior leadership roles and joined the Executive Committee in 2011 when he was appointed head of Sanofi Pasteur. He later led China and Emerging Markets, underscoring his international scope and his ability to manage highly regulated, complex businesses. Before and alongside his large-cap pharmaceutical experience, Jean-Louis Ménard made his mark in the contract research organization (CRO) space by developing and leading MAPI from 1981 to 2017, until the company was sold to the Irish CRO ICON. That long tenure gave him deep expertise in clinical research services, outsourcing models, biotech partnerships, and the scaling of science-driven businesses. He is now president of EOLYS, a group comprising five SMEs, and he reinvests in high-potential companies, including genOway, where he acts as both shareholder and board member. This combination of entrepreneurial investment and operational leadership gives him a strong understanding of growth-stage healthcare companies. At genOway, a listed company focused on preclinical research models and solutions for biopharma clients, his role on the board supports governance, strategic oversight, and long-term value creation. His background is particularly relevant to genOway’s positioning, as it blends scientific credibility with commercial discipline and international development experience. He brings a rare mix of medical training, legal knowledge, operational management, and sector expertise, making him a valuable figure in French corporate governance within the life sciences ecosystem.
